Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1998-11-25
2001-08-07
Borin, Michael (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007210, C436S501000, C514S002600
Reexamination Certificate
active
06270979
ABSTRACT:
FIELD OF THE INVENTION
The present invention generally relates to G protein coupled receptors, and more particularly to assays for determining certain activities of G protein receptors, such as opioid &mgr; receptors, and treatments using anti-addictive agents determinable therefrom.
BACKGROUND OF THE INVENTION
G protein coupled receptors (hereinafter sometimes termed “GPCR”s) comprise a large superfamily of receptors sharing a common structural motif of seven transmembrane helical domains. When a ligand (an agonist) binds to a GPCR and activates it, signal transduction is achieved through the intermediary G protein (a heterotrimeric GTP binding protein) which in turn activates the second messenger system. Although the exact nature of the receptor-G protein interactions is not yet known, the receptor activated regulatory cycle of the G protein involves GTP exchange for GDP, dissociation of the &agr; and &bgr;&ggr; subunits, activation of the second messenger pathway by GTP-G
60
and &bgr;&ggr;, and termination of activation upon GTP hydrolysis to GDP by the inherent GPTase activity of the &agr; subunit. G protein coupled receptors regulate virtually all bodily functions ranging from vision and olfaction to neuronal and endocrine signaling.
A general property of signal transduction mediated by G protein coupled receptors is the attenuation of signaling upon prolonged agonist stimulation. These processes are referred to as desensitization, tachyphylaxis, adaptation, tolerance, or quenching. Because signal attenuation limits the clinical uses of many pharmaceuticals acting on GPCRs, the mechanism for this process has been the focus of much research. Receptor phosphorylation by selective kinases of G protein coupled receptors (termed “GRK”s) has been shown to contribute to desensitization of several receptors. To date, no selective and or potent GRK inhibitors have been reported, other than heparin which does not penetrate into intact cells, even though such inhibitors might prevent desensitization in these cases (e.g., the &bgr;2 receptor). GRKs selectively polyphosphorylate only the active receptor state, which not only serves as a preferred substrate, but also directly stimulates GRK activity.
Another emerging recognized feature of a number of GPCRs is the presence of a basal level of signaling activity, occurring in the absence of any agonist ligand. Mutations inducing high basal activity have been associated with genetic disorders, demonstrating the physiological relevance of basal receptor activity. For GPCRs displaying basal activity, two classes of antagonist have been defined, i.e., neutral antagonists which block only agonist induced effects without changing basal activity, and inverse agonists, or negative antagonists (or inverse agonists), which also block basal receptor activity.
Prior assay attempts to detect any significant changes of the &mgr; opioid receptor system during prolonged agonist exposure have been unable to determine biochemical mechanisms underlying narcotic addiction. Thus, much of the current research work has focused on events downstream of the receptor, such as long-term gene regulation, in attempting to account for the dependent-tolerant state. Because tolerance and the dependence liability of narcotic drugs severely limit their clinical utility as potent analgesics and exert a heavy toll on society through illicit narcotic drug use, a screen for agents that could prevent or reverse the narcotic dependent-tolerant state or might facilitate gradual withdrawal would greatly enhance the clinical utility of narcotic analgesics and could serve as an effective pharmacological weapon in the fight against illicit drug use.
SUMMARY OF THE INVENTION
One aspect of the present invention is to provide a means for assaying or measuring the regulation of the addictive state, in the search for compounds that prevent or reverse constitutive &mgr; receptor activation, and to classify test compounds for their effects on the constitutively active &mgr; receptor state.
Other aspects of the present invention are methods for treating patients who are addicted to a narcotic analgesic, or who have taken an overdose of a narcotic analgesic, or whose pain is being relieved with a narcotic analgesic. Therapeutic methods in accordance with the invention normally involve selection of an agent with desired effects on the constitutive activation of opioid &mgr; receptors. These desired effects are determinable from the inventive assays.
Accordingly, practice of the invention is expected greatly to enhance the clinical utility of narcotic analgesics and to serve as effective pharmacological weapons in the fight against illicit drug use.
REFERENCES:
patent: 5061715 (1991-10-01), Sunkara et al.
patent: 6007986 (1999-12-01), Sadee
Biedler et al., “Morphology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture,”Cancer Research, 33,pp. 2643-2652 (Nov. 1973).
Costa et al., “Drug Efficacy at Guanine Nucleotide-Binding Regulatory Protein-Linked Receptors: Thermodynamic Interpretation of Negative Antagonism and of Receptor Activity in the Absence of Ligand,”Molecular Pharmacology, 41,pp. 549-560 (1992).
Frey and Kebabian, “A &mgr;-Opiate Receptor in 7315c Tumor Tissue Mediates Inhibition of Immunoreactive Prolactin Release and Adenylate Cyclase Activity,”Endocrinology, 115(5), pp. 1797-1804 (1984).
Kogan et al., “Elevated Basal Firing Rates and Enhanced Responses to 8-Br-cAMP in Locus Coeruleus Neurons in Brain Slices from Opiate-Dependent Rats,”European Journal of Pharmacology, 211,pp. 47-53 (1992).
Nestler, Eric J., “Molecular Mechanisms of Drug Addiction,”The Journal of Neuroscience, 12(9), pp. 2439-2450 (Jul. 1992).
Rasmussen et al., “Opiate Withdrawal and the Rat Locus Coeruleus: Behavioral, Electrophysiological, and Biochemical Correlates,”The Journal of Neuroscience, 10(7), pp. 2308-2317 (Jul. 1990).
Sibinga and Goldstein, “Opioid Peptides and Opioid Receptors in Cells of the Immune System,”Ann. Rev. Immunolo., 6,pp. 219-249 (1988).
Yu et al., “A Human Neuroblastoma Cell Line Expresses &mgr;and &dgr;Opioid Receptor Sites,”The Journal of Biological Chemistry, 261,pp. 1065-1070 (1986).
Abdelhamid and Takemori, “Characteristics of &mgr;and &dgr;Opioid Binding Sites in Striatal Slices of Morphine-Tolerant and -dependent Mice,”Journal of Pharmacology, 198,pp. 157-163 (1991).
Sharma et al., Dual Regulation of Adenylate Cyclase Accounts for Narcotic Dependence and Tolerance,Proc. Nat. Acad. Sci. USA, 72(8), pp. 3092-3096 (Aug. 1975).
Saée et al., “Constitutive Activation of the &mgr;-Opioid Receptor: A Novel Paradiagm of Receptor Regulation in Narcotic Analgesia, Tolerance, and Dependence,”Analgesia, 1(1), pp. 11-14 (1994).
Lameh et al., “Agonist Induced Conversion of the Hm1 Muscarinic Cholinergic Receptor to a Constitutively Active State: A Novel Papadign of Receptor Regulation,” p. 57 of the program for Subtypes of Muscarinic Receptors: The 6thInternational Symposium, sponsored by Boston University School of Medicine and Johann Wolfgang-Goethe University, held in Fort. Lauderdale, Florida, Nov. 9-12, 1994.
Baker, Mitzi, “New Hypothesis on How Narcotics Produce Tolerance, Dependency,”Synapse(newspaper of the University of California, San Francisco), 39(15), pp. 1 and 5 (Jan. 12, 1995).
Högger et al., “Activating and Inactivating Mutations in N- and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors,”The Journal of Biological Chemistry, 270(13), pp. 7405-7410 (1995).
Wang et al., “Agonist Induced Constitutive Activation of the &mgr; Opioid Receptor by Phosphorylation,”Regulatory Peptides, 54(1), pp. 323-324 (1994).
Yu and Sadée,“Efficacy and Tolerance of Narcotic Analgesics at the Mu Opiod Receptor in Differentiated Human Neuroblastoma Cells,”The Journal of Pharmacology and Experimental Therapeutics, 245(1), pp. 350-355 (1988).
Yu et al., “Differentiation of Human Neuroblastoma Dells: Marked Potentiation of Prostaglandin E-Stimulated Accumulation of Cyclic AMP by Retinoic Acid,”Journal of Neurochemistry, 51(6), pp. 1892-1
Borin Michael
The Regents of the University of California
LandOfFree
Methods for anti-addictive narcotic analgesic treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for anti-addictive narcotic analgesic treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for anti-addictive narcotic analgesic treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2503319